Abstract
Four case reports are described in which adjunctive alprazolam was administered to schizophrenic or schizoaffective patients who satisfied criteria for the syndrome of 'negative symptoms'. The addition of alprazolam to ongoing neuroleptic and antiparkinsonian drug treatment produced substantial clinical benefit in only one of these cases, and that benefit was not replicated in a second trial in this case. These results are discussed in comparison to previously reported findings in other alprazolam-treated 'negative symptom' patients.
| Original language | English |
|---|---|
| Pages (from-to) | 326-328 |
| Number of pages | 3 |
| Journal | Canadian Journal of Psychiatry |
| Volume | 34 |
| Issue number | 4 |
| State | Published - Jan 1 1989 |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Trials of adjunctive alprazolam in 'negative symptom' patients. / Adan, F.; Siris, S. G.
In: Canadian Journal of Psychiatry, Vol. 34, No. 4, 01.01.1989, p. 326-328.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trials of adjunctive alprazolam in 'negative symptom' patients
AU - Adan, F.
AU - Siris, S. G.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - Four case reports are described in which adjunctive alprazolam was administered to schizophrenic or schizoaffective patients who satisfied criteria for the syndrome of 'negative symptoms'. The addition of alprazolam to ongoing neuroleptic and antiparkinsonian drug treatment produced substantial clinical benefit in only one of these cases, and that benefit was not replicated in a second trial in this case. These results are discussed in comparison to previously reported findings in other alprazolam-treated 'negative symptom' patients.
AB - Four case reports are described in which adjunctive alprazolam was administered to schizophrenic or schizoaffective patients who satisfied criteria for the syndrome of 'negative symptoms'. The addition of alprazolam to ongoing neuroleptic and antiparkinsonian drug treatment produced substantial clinical benefit in only one of these cases, and that benefit was not replicated in a second trial in this case. These results are discussed in comparison to previously reported findings in other alprazolam-treated 'negative symptom' patients.
UR - http://www.scopus.com/inward/record.url?scp=0024319587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024319587&partnerID=8YFLogxK
M3 - Article
C2 - 2736478
AN - SCOPUS:0024319587
VL - 34
SP - 326
EP - 328
JO - Canadian Journal of Psychiatry
JF - Canadian Journal of Psychiatry
SN - 0706-7437
IS - 4
ER -